24 February 2026: Articles
Delayed but Salvaged: Rhodococcus Lung Abscess in a Patient With Undiagnosed HIV/AIDS
Mistake in diagnosis, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Tuzahira Arshad WaliDOI: 10.12659/AJCR.951229
Am J Case Rep 2026; 27:e951229
Abstract
BACKGROUND: Rhodococcus species is an opportunistic pathogen in immunocompromised conditions, including HIV/AIDS. It primarily causes necrotizing pneumonia and can clinically mimic pulmonary tuberculosis (TB), which is relevant in settings with a high TB burden, such as Pakistan. This case report presents a late diagnosis of HIV/AIDS associated with Rhodococcus lung abscess, which was initially treated as pulmonary TB and lung abscess.
CASE REPORT: A man in his 30s presented with a 1-month history of fever, weight loss, cough, night sweats, and chest pain. He denied exposure to soil or horses. He received empiric treatment for suspected pulmonary TB and lung abscess, with poor clinical response. A CT-guided lung biopsy confirmed the microbiological diagnosis of Rhodococcus lung abscess approximately 3 to 4 months after the symptom onset. HIV screening was unfortunately delayed due to the rarity and poor awareness of Rhodococcus as an opportunistic pathogen in the HIV population. AIDS was diagnosed 5 months after symptom onset. Antiretroviral therapy and culture-directed treatment for Rhodococcus lung abscess was initiated, with good clinical outcome.
CONCLUSIONS: Pakistan ranks fifth globally among high-burden TB countries and yet lacks healthcare resources. Prompt recognition of Rhodococcus infection should trigger HIV screening and early multidisciplinary management, to optimize outcomes in resource-limited, TB-endemic settings.
Keywords: AIDS-Related Opportunistic Infections, Case Reports, HIV Infections, Immunocompromised Host, Lung
Introduction
Case Report
INITIAL PRESENTATION:
A previously healthy non-smoking man in his late 30s presented to the pulmonology clinic with a 1-month history of intermittent high-grade fever, night sweats, weight loss of 10 kg, dry cough, and left pleuritic chest pain. He denied drug allergies, recent travel, or substance abuse. He was married, worked at the airport, and reported no exposure to animals or soil.
DIAGNOSTIC WORKUP:
Chest X-ray showed left hilar lymphadenopathy and ill-defined opacity in the left lower zone (Figure 1A). HIV testing and sputum acid-fast bacilli studies were ordered; they were neither performed nor followed up in the pulmonology clinic. Blood cultures were not done. Chest computed tomography (CT) showed a 55×41 mm cavitating soft tissue lesion in left lower lobe, left hilar lymphadenopathy, and few enlarged mediastinal lymph nodes (Figure 1B).
THERAPEUTIC COURSE:
The patient sought a second opinion from another tuberculosis (TB) treatment center. Approximately 5 weeks after symptom onset, he was started on empiric anti-tuberculous therapy with HREZ (isoniazid, rifampicin, ethambutol, pyrazinamide), oral clindamycin 300 mg 3 times daily, and ceftriaxone 1 g IV twice daily for suspected pulmonary TB and lung abscess, respectively. Dexamethasone was given for a week for an unclear indication. An ultrasound-guided lung biopsy was planned but not performed, due to poor follow up and lack of care coordination.
Three weeks after anti-tuberculous therapy initiation, oral levofloxacin was added for persistent symptoms. Seven weeks after therapy initiation, a follow-up chest CT showed worsened left lower lobe cavitation measuring 60×49 mm (Figure 1C). Subsequently, the CT-guided lung biopsy procedure was re-initiated, contingent upon confirming patient adherence. Ten milliliters of frank pus was aspirated. While cultures results were pending, clindamycin and ceftriaxone were re-prescribed, and voriconazole 200 mg twice daily was added empirically. Gram staining showed numerous pus cells and few gram-positive rods, initially identified as Corynebacterium spp. Final growth isolated Rhodococcus spp.; however, speciation could not be done, as shown in Table 1, which details the antimicrobial susceptibility testing of Rhodococcus spp.
Anaerobic, fungal, and mycobacterial cultures were negative. Histopathology showed moderate interstitial inflammation and focal fibrin. Results were negative for malignancy or granuloma. Clindamycin and voriconazole were stopped. Anti-tuberculous therapy was discontinued after 9 weeks. The administration of parenteral linezolid was added to the ceftriaxone.
The infectious disease department was consulted more than a month after
The patient’s course was complicated by polymicrobial gram-negative pneumonia approximately 5 to 6 weeks after ART initiation. He developed a new-onset cough, fever, and hemoptysis. Repeat CT of the chest revealed 87×80 mm left lower lobe cavitary consolidation, surrounding centrilobular nodules, mild left-sided pleural effusion and multiple enlarged left hilar lymph nodes (Figure 1D). Bronchoalveolar lavage identified Klebsiella species and Pseudomonas aeruginosa (Tables 2, 3). Fungal and acid-fast bacilli cultures were negative. The cytology report showed acute inflammation with macrophages and columnar cells admixed with mucus. Culture-directed therapy with ertapenem for 1 week was prescribed for Klebsiella. For P. aeruginosa, ciprofloxacin was started. Unfortunately, the patient developed shivering, rigors, and fever after the first dose of ciprofloxacin, leading to discontinuation. Moxifloxacin was held off initially then resumed with no intolerance (Figure 2).
FOLLOW-UP:
As of this writing, the patient is taking a 7-month course of oral moxifloxacin and linezolid. A follow-up CT of the chest showed marked interval resolution (Figure 3). He has returned to work and has adhered to ART, with a CD4 count of 221 cells/mm3 and viral load of 187 copies/mL.
Discussion
There is paucity of literature on
Our case provides a real-world example that underscores the numerous obstacles clinicians must overcome in diagnosis and management, which are chiefly attributable to the country’s poor healthcare infrastructure. These challenges are highly intricate and interlinked. Diagnostically, HIV screening and image-guided lung biopsy were delayed. Acid-fast bacilli studies were also not done.
Retrospective analysis suggested the issue stemmed largely from a lack of continuous care, a problem intensified by several factors: poor communication between the 2 treatment centers, the patient seeking care elsewhere, and the failure to maintain coordinated records, despite the involvement of a teaching hospital. After the
The clinical manifestations of
Treatment includes combination antibiotics with at least 2 agents in immunocompromised hosts. For initial therapy, a macrolide or fluoroquinolone in combination with rifampin or with 2 of the following is recommended: vancomycin, imipenem, linezolid, or an aminoglycoside. It is preferred to use antibiotics with intracellular activity, such as rifampin, fluoroquinolones, and azithromycin, because survival within histiocytes is a significant virulence determinant in
Conclusions
There is an acute need for a robust healthcare delivery system in Pakistan, a major contributor to global TB burden and the third-highest antimicrobial consuming country among low- and middle-income countries.
Figures
Figure 1. (A) Left hilar lymphadenopathy with ill-defined opacity in the left lower zone (white arrows). (B) Left lower lobe cavitation measuring 55×41 mm (black arrow). (C) Follow-up chest CT: worsened cavitation measuring 60×49 mm, surrounding consolidation, air bronchograms, nodular infiltrates (black arrow). (D) Worsening left lower lobe consolidation, measuring 87×80 mm (black arrow).
Figure 2. Antibiotic treatment timeline and duration.
Figure 3. Interval resolution. Left lower lobe small dense chronic cavitating consolidation and fibrotic changes (yellow arrow). Tables
Table 1. Antimicrobial susceptibility testing of Rhodococcus spp.
Table 2. Antimicrobial susceptibility testing of Klebsiella spp. on bronchoalveolar lavage.
Table 3. Antimicrobial susceptibility testing of Pseudomonas aeruginosa on bronchoalveolar lavage.
Table 4. Reported cases of Rhodococcus infection from Pakistan.
References
1. Weinstock DM, Brown AE: Clin Infect Dis, 2002; 34(10); 1379-85
2. Yamshchikov AV, Schuetz A, Lyon GM: Lancet Infect Dis, 2010; 10(5); 350-59
3. Zhu H, Guo Y, Chen H: Infect Drug Resist, 2025; 18; 2021-27
4. Wahab R, Ahad A, Rahman HU, Surgical management of Rhodococcus induced anterior mediastinal mass: A case report: Respir Med Case Rep, 2024; 52; 102121
5. Babar ZU, Nasim A, Dodani SK, Aziz T: Saudi J Kidney Dis Transpl, 2023; 34(4); 365-70
6. Khan MY, Ali S, Baqi S: J Pak Med Assoc, 2013; 63(5); 635-38
7. Watanabe H, Kobayashi S, Watanabe K: J Infect Chemother, 2000; 6(4); 229-32
8. Vergidis P, Ariza-Heredia EJ, Nellore A, Rhodococcus infection in solid organ and hematopoietic stem cell transplant recipients: Emerg Infect Dis, 2017; 23(3); 510-12
9. Meeuse JJ, Sprenger HG, van Assen S: Emerg Infect Dis, 2007; 13(12); 1942-43
10. Russo G, Lichtner M, Carnevalini M: Int J Infect Dis, 2010; 14(6); e533-35
11. Xu X, Liang H, Song Y: Infect Med (Beijing), 2022; 1(4); 281-84
12. Vechi HT, Oliveira ETG, Freitas MR: Rev Inst Med Trop Sao Paulo, 2018; 60; e74
13. Khan MA, Bilal W, Asim H, MDR-TB in Pakistan: Challenges, efforts, and recommendations: Ann Med Surg (Lond), 2022; 79; 104009
14. World Health Organization: WHO consolidated guidelines on tuberculosis. Module 6: Tuberculosis and comorbidities [online] Apr 22, 2024, World Health Organization Available from: https://www.who.int/publications/i/item/9789240087002
15. Lin WV, Kruse RL, Yang K, Musher DM: Clin Microbiol Infect, 2019; 25(3); 310-15
16. Torumkuney D, Jamil B, Nizamuddin S, Country data on AMR in Pakistan in the context of community-acquired respiratory tract infections: Links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome: J Antimicrob Chemother, 2022; 77(Suppl 1); 118-25
17. Kedlaya I, Ing MB, Wong SS: Clin Infect Dis, 2001; 32(3); E39-46
18. Siavashifar M, Rezaei F, Motallebirad T: Genes Environ, 2021; 43(1); 2
Figures
Figure 1. (A) Left hilar lymphadenopathy with ill-defined opacity in the left lower zone (white arrows). (B) Left lower lobe cavitation measuring 55×41 mm (black arrow). (C) Follow-up chest CT: worsened cavitation measuring 60×49 mm, surrounding consolidation, air bronchograms, nodular infiltrates (black arrow). (D) Worsening left lower lobe consolidation, measuring 87×80 mm (black arrow).
Figure 2. Antibiotic treatment timeline and duration.
Figure 3. Interval resolution. Left lower lobe small dense chronic cavitating consolidation and fibrotic changes (yellow arrow). Tables
Table 1. Antimicrobial susceptibility testing of Rhodococcus spp.
Table 2. Antimicrobial susceptibility testing of Klebsiella spp. on bronchoalveolar lavage.
Table 3. Antimicrobial susceptibility testing of Pseudomonas aeruginosa on bronchoalveolar lavage.
Table 4. Reported cases of Rhodococcus infection from Pakistan.
Table 1. Antimicrobial susceptibility testing of Rhodococcus spp.
Table 2. Antimicrobial susceptibility testing of Klebsiella spp. on bronchoalveolar lavage.
Table 3. Antimicrobial susceptibility testing of Pseudomonas aeruginosa on bronchoalveolar lavage.
Table 4. Reported cases of Rhodococcus infection from Pakistan. In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






